Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M Llinares Esquerdo"'
Autor:
IP Jiménez-Pulido, S Martínez-Pérez, A Navarro Ruiz, S Gutierrez-Palomo, A Garcia-Monsalve, M Llinares-Esquerdo
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Stomatitis is a class effect associated with inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce the incidence and severity of stomatitis. Aim and objectives To descr
Autor:
M Pomares-Bernabeu, S Martínez-Pérez, IP Jiménez-Pulido, M Llinares-Esquerdo, A Navarro Ruiz, G Miralles-Andreu
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance According to the EMA product information, in Crohn’s disease (CD), ustekinumab is dosed first by intravenous administration. Patients should then continue with 90 mg ustekinumab subcutaneous every 8 (q8W) or 12 (q12W) week
Autor:
A Navarro Ruiz, S Martínez-Pérez, M Llinares-Esquerdo, S Gutierrez-Palomo, G Miralles-Andreu, A Garcia-Monsalve
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Despite advances in the early detection and treatment of cancer, a large proportion of patients still eventually die as a result of their disease. The quality of medical care delivered to cancer patients near the end of life
Autor:
M Pomares-Bernabeu, A Navarro Ruiz, IP Jiménez-Pulido, L Sorian-Irigaray, S Martínez-Pérez, M Llinares-Esquerdo
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Palliative care can improve the quality of life in patients with advanced cancer. However, WHO data indicate that only 14% of people who need palliative assistance take advantage of it. Aim and objectives To evaluate therape
Autor:
A Navarro Ruiz, AC Murcia López, L Soriano Irigaray, M Pomares Bernabeu, G Miralles Andreu, M Llinares Esquerdo
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Nivolumab was authorised in Spain in 2015. It is a human immunoglobulin monoclonal antibody that binds to PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is indicated in adjuvant or metastatic melanoma (MC)
Autor:
M Llinares Esquerdo, S Martínez-Pérez, A Navarro Ruiz, AC Murcia López, AM Sánchez García, L Soriano Irigaray
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The lack of adherence to the pharmacological treatment of patients with chronic diseases is a prevalent and relevant problem in routine clinical practice. Purpose To assess the degree of adherence to the non-chemotherapy intravenous treatm
Autor:
S Martínez-Pérez, M Llinares-Esquerdo, A Navarro Ruiz, Ana Cristina Murcia-López, A Garcia-Monsalve, AM Sanchez-Garcia
Publikováno v:
Eur J Hosp Pharm
Background Critically ill patients experience many pathophysiological changes that can affect the effectiveness of pharmacological treatment. Purpose To describe the recommendations of dosage and monitoring of vancomycin used in the intensive care un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251cc81222481cc9a1fd537e0f49827b
https://europepmc.org/articles/PMC7535208/
https://europepmc.org/articles/PMC7535208/
Autor:
A Garcia-Monsalve, M Llinares-Esquerdo, A Navarro Ruiz, C Matoses-Chirivella, S Martínez-Pérez, E Garcia-Iranzo
Publikováno v:
Eur J Hosp Pharm
Background In recent years, there has been increased use of plasma rich in growth factors (PRGF-Endoret) which is extracted from the patient’s blood in order to treat ocular surface diseases. PRGF is a promising tool in ocular surface diseases due
Autor:
M Llinares Esquerdo, A Navarro Ruiz, R Antón Torres, A Andújar Mateos, AM Sánchez García, L Soriano Irigaray
Publikováno v:
Eur J Hosp Pharm
Background Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. Purpose To compare the effectiveness of AA and